PepTrackevidence-graded reference
Selank
fig.1 — stylized molecular motif
Cognitive

Selank

TP-7 · tuftsin analog

Top nootropic-peptide searches ('Selank vs Semax'); marketed as a non-stimulant, non-dependence benzo alternative.

Evidence
Bhuman trials
Status
Category 2 — restrictedas of 2026-06
Approval
Not approved
Category
Cognitive
Route
Intranasal · Subcutaneous
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
Intranasal ~300-450 mcg/day (Russian label); SubQ is community-only
Titration
Cycles ~14 days then washout
Reconstitution — illustrative, not a recommendation
SubQ (community): 5 mg vial + 2 mL BAC = 2.5 mg/mL; 250 mcg = 10 U on U-100. Intranasal is the trial route - dose by mcg/spray.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. No active US compounding pathway; treat as gray-market RUO. Verify against FDA docket.
Status
Category 2 — restricted
503A bulks
Not on the bulks list
Category 2
Removed earlier (Sept 2024 referral) but NOT in the Apr 2026 wave or Jul 2026 PCAC; vendor 'returned to Category 1' claims are FALSE
PCAC review
none scheduled
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows

Small Russian human data (Medvedev 2008, n=62: anxiolytic comparable to benzodiazepine); unreplicated in the West. Russia-approved nasal drops since 2009.

04Safety
Contraindications
  • Pregnancy/breastfeedinghard stop
  • Children
  • Hypersensitivity
Key interactions
  • Serotonergic agents (SSRI/SNRI/MAOI) - theoretical serotonin-syndrome additive risk (caution, low confidence)
  • Benzodiazepines (animal-derived synergy claim - extrapolation)
Serious signals
  • Long-term safety unknown (longest trials ~30 days)
  • Gray-market integrity/immunogenicity
Monitoring
None validated.
05Related in Cognitive
Semax
human trials
grade B →
06Sources
1Medvedev 2008
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium
← All peptides
Cognitive

Selank

TP-7 · tuftsin analog

Top nootropic-peptide searches ('Selank vs Semax'); marketed as a non-stimulant, non-dependence benzo alternative.

Evidence
B
human trials
Status
Category 2 — restricted
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Intranasal · Subcutaneous
Clinic protocol
Demand
—
honorable mention
WADA
Not listed
sport-legal
01

Dosing & protocol

Clinic protocol. Clinic-protocol / off-label extrapolation — not an FDA-approved regimen.
Typical — reference only

Intranasal ~300-450 mcg/day (Russian label); SubQ is community-only

Worked reconstitution example

SubQ (community): 5 mg vial + 2 mL BAC = 2.5 mg/mL; 250 mcg = 10 U on U-100. Intranasal is the trial route - dose by mcg/spray.

Titration

Cycles ~14 days then washout

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. No active US compounding pathway; treat as gray-market RUO. Verify against FDA docket.
StatusCategory 2 — restricted
503A bulksNot on the bulks list
Category 2 (2026)Removed earlier (Sept 2024 referral) but NOT in the Apr 2026 wave or Jul 2026 PCAC; vendor 'returned to Category 1' claims are FALSE
PCAC reviewnone scheduled
WADANot listed
03

Evidence — the honest read

Bhuman trials

Small Russian human data (Medvedev 2008, n=62: anxiolytic comparable to benzodiazepine); unreplicated in the West. Russia-approved nasal drops since 2009.

04

Safety

Contraindications
  • Pregnancy/breastfeedinghard stop
  • Children
  • Hypersensitivity
Key interactions
  • Serotonergic agents (SSRI/SNRI/MAOI) - theoretical serotonin-syndrome additive risk (caution, low confidence)
  • Benzodiazepines (animal-derived synergy claim - extrapolation)
Serious signals
  • Long-term safety unknown (longest trials ~30 days)
  • Gray-market integrity/immunogenicity
Monitoring

None validated.

06

Sources

01Medvedev 2008
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium